Last reviewed · How we verify

NCT03883347

Sedation With Dexmedetomidine Versus Remifentanil in Urogynecological Surgery Under Spinal Anaesthesia

Status unknown Phase 3 Last updated 14 October 2019
What this trial tests

Phase 3 trial testing Dexmedetomidine in Vaginal Hysterectomy in 50 participants. Status unknown.

Timeline
20 March 2019
Primary endpoint
20 March 2022
20 April 2022

Quick facts

Lead sponsorUniversity of Athens
PhasePhase 3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment50
Start date20 March 2019
Primary completion20 March 2022
Estimated completion20 April 2022
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

University of Athens

Who can join

Adults 40 to 75, female only, with Vaginal Hysterectomy or Suburethral Slings. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neuraxial blocks are usually used as an anaesthetic method for urogynecological surgeries. In most patients under regional anaesthesia, premedication is given for reducing anxiety. Purpose of this prospective double blind randomised clinical trial is the investigation of the effect of perioperative intravenous infusion of dexmedetomidine vs remifentanil for sedation in patients under spinal anaesthesia for urogynecological procedures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Vaginal Hysterectomy

Currently open trials in the same condition.

Other University of Athens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03883347.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing